Updates in Anticoagulation Therapy
New blood thinners offer advantages
New anticoagulants are moving into the field traditionally dominated by warfarin and heparin.
These direct oral anticoagulants (DOACs) can prevent dangerous blood clots in people with such conditions as valvular atrial fibrillation (a-fib).
Although warfarin (Coumadin and Jantoven) often works well, it calls for frequent medical supervision and interacts poorly with many foods and other medications. Heparin is a generic blood thinner.
Updates in anticoagulation therapy include medicines that are more patient-friendly: apixaban, dabigatran and rivaroxaban, which can be taken orally once or twice a day.
New DOACs
Apixaban, sold under the brand name Eliquis, can treat and prevent blood clots and prevent stroke in people with nonvalvular atrial fibrillation. It does this by directly inhibiting factor Xa, which promotes unwanted clotting.
Dabigatran (Pradaxa) can treat deep vein thrombosis and reduce the risk of a recurrence. Dabigatran inhibits thrombin, an enzyme that helps blood to clot. It is also used to help prevent strokes or serious blood clots in adults who have atrial fibrillation.
Rivaroxaban (Xarelto) blocks factor Xa, a pro-clotting enzyme. It is used in patients who have deep vein thrombosis or pulmonary embolism or who may face a recurrence.
You can learn much more about DOACs at www.medicalnewstoday.com/articles/anticoagulant-drugs
Friendly service, a great selection of items and free delivery are just three benefits of shopping at LVRX Pharmacy.